Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 03:00 ET | Source: Cyprumed GmbH

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive up to $493 million in upfront, development, regulatory...